Prostate Cancer Videos
Latest Prostate Cancer News
Meta-analysis shows that use of medication is associated with an 18% lower risk.
Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.
Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.
Adding bicalutamide improves overall survival among patients with advanced nonmetastatic hormone-naïve prostate cancer.
Cancer-specific and overall survival is decreased in men with intermediate-risk versus low-risk tumors.
Researchers observed a significant 36% decreased overall and prostate cancer-specific mortality.
The 4Kscore enables better identification of men who harbor high-grade prostate cancer.
The 5-year risk of overall mortality is decreased by 50% compared with androgen deprivation therapy alone.
This medication sequence was associated with longer progression-free and overall survival compared with the reverse.
Researchers found elevated familial risks for testicular, prostate, bladder, and kidney cancers.
Prostate cancer progression was delayed by a median 10 months in statin users.
A history of testicular cancer was associated with a greater likelihood of prostate cancer overall and intermediate- or high-risk disease.
No higher risk of adverse pathology among men on active surveillance who delayed surgery until signs of disease progression.
The proportion of men diagnosed with intermediate- or high-risk disease rose 6% from 2011 to 2013, study finds.
Risk factors include male gender, distant disease, increasing age, race/ethnicity
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)